Saxena et al Zetomipzomib, a selective immunoproteasome inhibitor in lupus nephritis. Phase 2 study. UPCR=<0.5 achieved 64.7% week 37, pred=<10mg/day 82.4% week 13. @RheumNow #ACR22 Abstr#0992 https://t.co/askpmqsYYG https://t.co/cKoR0bgtWt
Links:
Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616…
https://acrabstracts.org/abstract/interim-results-from-the-phase-2-mission-stud…
13-11-2022
